List of APIs/Active Pharmaceutical Ingredients Companies with Phase 4 Active Clinical Trial - 10

Amneal Pharmaceuticals, Inc. (NYSE: AMRX) is an integrated specialty pharmaceutical company powered by a robust U.S. generics business and a growing branded business. Together, our team is working to build one of the most dynamic pharmaceutical companies in our rapidly changing industry.

Cipla is a leading global pharmaceutical company trusted by healthcare professionals and patients across the world since 1935. A compassionate approach to healthcare that goes beyond the pursuit of profit and growth has been the force impelling Cipla’s history over the years. Our credo and our purpose of ‘Caring for Life' continues to guide our actions towards our people and the planet for creating a sustainable future. Cipla today has presence in 80+ countries, providing over 1,500 products across various therapeutic categories in 50+ dosage forms. Keeping with our legacy of care, we constantly strive to ensure access to high-quality medicines that make a difference in the lives of patients. Our paradigm-changing offer of a triple anti-retroviral (ARV) therapy in HIV/AIDS at less than a dollar a day in Africa in 2001 was pivotal in bringing inclusiveness, accessibility and affordability to the centre of the HIV movement. An unmatched presence across the care continuum (awareness, prevention, diagnosis, treatment and adherence) and the widest range of drug-device combinations has established Cipla’s respiratory leadership in India and other key emerging markets. Armed with this legacy and a deep understanding of the lungs, we have articulated our aspiration to become a global lung leader and help millions breathe free.

CSPC Pharmaceutical Group Limited is a leading pharmaceutical company based in Shijiazhuang, Hebei, China. The company focuses on the research, development, manufacture, and sale of a wide range of pharmaceutical products. With a strong emphasis on innovation, CSPC has a robust research and development team of over 2,000 members, including many with advanced degrees and international experience. Their R&D efforts span multiple locations, including Shijiazhuang, Shanghai, Beijing, and the United States. CSPC offers a diverse array of pharmaceutical products, including finished drugs like capsules, tablets, and injections, as well as bulk drugs such as active pharmaceutical ingredients. Their product range addresses various therapeutic areas, including oncology, cardiovascular health, respiratory conditions, anti-infectives, and diabetes management. The company also has an extensive pipeline of over 300 projects focused on innovative drug development, highlighting its commitment to advancing healthcare solutions. CSPC's products are available in multiple regions, including the Americas, Europe, and Asia, serving a broad customer base in the healthcare sector.

Infusing Innovation In Everything We Do Looking for hemp-derived CBD ingredients of the highest quality, purity and consistency? Need a proven source for premium bulk and differentiated finished goods, whose mandate to champion innovation, science and compliance leads the field? Explore how the beneficial properties of CBD can enhance your product’s impact and value — in food and beverage, creams and other topicals, pet products and more. Trust a genuine industry pioneer. Partner with GenCanna. Since our inception in 2014, GenCanna has remained at the vanguard of today’s now booming CBD industry, because our influential founders helped create it. Literally. Vetted, tested and proven over time, this makes us your smartest, surest choice in a full-service CBD partner. Our roots extend back to the earliest days of cannabis legalization and reform. GenCanna helped lead the introduction of Kentucky’s groundbreaking 2014 Hemp Pilot Program. We continue spearheading regulatory initiatives that open and accelerate industry growth. In short, GenCanna has remained at the heart of it all, earning the highest industry certifications, product validations and compliance accreditations to this day. Our scalable, premium-quality derivatives and differentiated finished goods bear witness to GenCanna’s unbridled commitment to excellence: • High-Quality Cannabinoid Isolates and Distillates • Premium Bulk Broad-Spectrum and Full-Spectrum Ingredients • Water-Soluble Liquids and Soluble Powders • Reserve Oils and Bottled Custom Oil Drops • Superior Custom Formulations: -Gummies -Capsules, soft gels, tablets, and other supplement form factors -Food and beverages -Broad range of cosmetics and topicals -Health and wellbeing topicals -Pet products • Turnkey Private Label Programs • White Label Products … you name it, we’ll infuse it! Ready to achieve the next level in CBD success? RELIABLE. INNOVATIVE. GENCANNA. Premium CBD ingredients that formulate profitability for you.

Givaudan is a global leader in Fragrance & Beauty and Taste & Wellbeing. We celebrate the beauty of human experience by creating for happier, healthier lives with love for nature. Together with our customers we deliver food experiences, craft inspired fragrances, and develop beauty and wellbeing solutions that make people look and feel good. With over 163 locations in 52 countries and over 78 production sites, of which 31 are located in Europe, 22 in North America, 17 in Latin America, 8 in Asia-Pacific, and 1 across South Asia, the Middle East, and Africa, we are committed to driving purpose-led growth that makes a positive impact. Givaudan: Human by nature. www.givaudan.com

INSUD PHARMA operates across the entire pharmaceutical value chain, delivering specialized expertise and experience in scientific research, development, manufacturing, sales and marketing of a wide range of value-adding active pharmaceutical ingredients (APIs), finished dosage forms (FDFs) and branded pharmaceuticals, for human and animal health. While the main offices are located in Madrid, Lugano, Buenos Aires, INSUD PHARMA is acting worldwide, creating a broad and balanced manufacturing and commercial network across Europe, America, Asia and Africa, to address global opportunities and customers`​ needs in all major pharmaceutical markets. INSUD PHARMA's activity is organized in three synergistic business areas: Industrial (Chemo), Branded (Exeltis) and Biotech (mAbxience), with over 7,300 professionals in more than 50 countries, 18 state-of-the-art facilities, 15 specialized R&D centers, 12 commercial offices and more than 35 pharmaceutical affiliates, serving 1,150 customers in 96 countries around the world. INSUD PHARMA believes in innovation and sustainable development. Our commitment is to improve people`s health and quality of life, providing access to quality medicines at affordable prices, and to continuously expand our efforts and R&D investment to develop new and better therapies.

Italfarmaco, one of the leading Italian pharmaceutical groups, operates in both the pharmaceutical and the fine chemical industries. The company was founded in Milan in 1938. The Italfarmaco Group now markets ethical products in Italy, Spain, Portugal and Greece, where it employs a workforce of over 1400 and has a total turnover exceeding 300 million euros. Its products, all of which have a high therapeutic content, are mainly used in the cardiovascular, immuno-oncological, gynaecological, dermatological, orthopaedic and neurological areas.

Qilu Pharmaceuticals is a leading Chinese pharmaceutical company founded in 1958, recognized as one of the top three players in China's pharmaceutical industry. The company operates as a vertically integrated enterprise, focusing on human medicines, veterinary medicines, and crop protection products. It has 12 subsidiaries and 11 manufacturing sites across China. Qilu's product portfolio includes over 300 finished dosage forms, making it a prominent manufacturer of injectables and solid-dose medications. The company also produces a wide range of active pharmaceutical ingredients (APIs) and has a robust pipeline with more than 200 generic drugs, 20–30 biosimilars, and 80–90 innovative drugs in development. With a global reach, Qilu exports products to over 100 countries and has established subsidiaries in the U.S., Europe, and Brazil. The company employs over 39,000 people worldwide, with a strong emphasis on affordable medicines and improving global health.

Sun Pharmaceutical Industries Ltd. (Sun Pharma) is a prominent global pharmaceutical company based in India. Established in 1983, it has grown to become the largest pharmaceutical company in India and the fifth-largest specialty generic pharmaceutical company worldwide. Sun Pharma specializes in generic and specialty pharmaceuticals, focusing on chronic therapies in areas such as cardiology, psychiatry, neurology, gastroenterology, and oncology. The company operates in over 100 countries, with significant markets in the U.S., India, and emerging economies. Sun Pharma produces a diverse range of off-patent generic drugs, including tablets, capsules, injectables, and topical formulations. It also develops complex generics and specialty products for various conditions. The company has a strong commitment to research and development, investing in novel drug delivery systems and biosimilars. With 43 manufacturing facilities across five continents and a workforce of over 37,000, Sun Pharma continues to expand its global footprint and enhance its product offerings.

Yuhan Corporation is an integrated healthcare company founded in 1926. It has achieved top market value and sales revenue in Korean pharmaceutical industries, and been awarded for the most respected and trusted company in Korea for recent 11 consecutive years. It has two subsidiaries, Yuhan Chemical and Yuhan Medica, and the affiliates including Joint Ventures with Janssen(Belgium), the Clorox Company(USA), and Kimbery-Clark Corporation(USA). The core business of Yuhan can be classified into Primary & Specialty care, Dietary supplement, Household & Animal care, and contract manufacturing of active pharmaceutical ingredients.